Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

by William Stohl, Milena Kurtinecz, David A Roth, Herbert Struemper, William W Freimuth, Lisa Edwards
Published 2022-02-01

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data

by Anne Hammer, Beulah Ji, David A Roth, David D'Cruz, Paige Meizlik, Gina Eriksson, Yulia Green
Published 2023-01-01

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort

by Qinggong Fu, Michelle A Petri, Daniel W Goldman, David A Roth, Selin Cooper Blenkinsopp, Yulia Green, Anuradha Madan, Patricia Juliao
Published 2022-08-01

EMBRACE: One Small Story in Lupus—One Giant Challenge in Clinical Trials

by Saira Z. Sheikh, Tessa R. Englund, Susan W. Burriss, Jonca Bull, Anya Harry, James G. Groark, Ashley M. Hall, Michelle Miller, David A. Roth
Published 2022-09-01

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

by Damon Bass, Regina Kurrasch, Yoshiya Tanaka, Sang-Cheol Bae, Beulah Ji, David A Roth, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik
Published 2021-07-01

1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)

by Brad H Rovin, Hans-Joachim Anders, Ming-hui Zhao, Ana Malvar, David A Roth, Keiju Hiromura, Jennifer Gilbride, Yulia Green, Anuradha Madan, Angela Jones- Leone, Tania Gonzalez-Rivera
Published 2022-12-01

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

by Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang
Published 2022-02-01

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

by Damon Bass, Regina Kurrasch, Yin Su, Jie Zheng, Yang Li, Guochun Wang, Fengchun Zhang, David A Roth, Jieruo Gu, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik, Mingjun Wang, Xingfu Li
Published 2022-04-01

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison

by Hermine I Brunner, Nicolino Ruperto, Clarissa A Pilkington, Damon L Bass, Mohamed Okily, Holly Quasny, Fengchun Zhang, Syuji Takei, Carlos Abud-Mendoza, Diego O Viola, Beulah N Ji, David A Roth, Masaaki Mori, Sandra Navarra, Reema Syed, Gina Eriksson, Anne E Hammer
Published 2021-11-01

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

by Xavier Mariette, Francesca Barone, Chiara Baldini, Hendrika Bootsma, Kenneth L. Clark, Salvatore De Vita, David H. Gardner, Robert B. Henderson, Michael Herdman, Karoline Lerang, Prafull Mistry, Raj Punwaney, Raphaele Seror, John Stone, Paul L.A. van Daele, André van Maurik, Nicolas Wisniacki, David A. Roth, Paul Peter Tak
Published 2022-12-01

Bottled water contaminant exposures and potential human effects

by Paul M. Bradley, Kristin M. Romanok, Kelly L. Smalling, Michael J. Focazio, Nicola Evans, Suzanne C. Fitzpatrick, Carrie E. Givens, Stephanie E. Gordon, James L. Gray, Emily M. Green, Dale W. Griffin, Michelle L. Hladik, Leslie K. Kanagy, John T. Lisle, Keith A. Loftin, R. Blaine McCleskey, Elizabeth K. Medlock–Kakaley, Ana Navas-Acien, David A. Roth, Paul South, Christopher P. Weis
Published 2023-01-01

Quantifying flow regimes in a Greenland glacial fjord using iceberg drifters

by Sutherland, David A., Roth, George E., Hamilton, Gordon S., Mernild, Sebastian H., Stearns, Leigh A., Straneo, Fiammetta
Published 2015